- Home
- PHAR vs CRML Comparison
PHAR vs CRML Comparison
Compare PHAR & CRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- CRML
- Stock Information
- Founded
- PHAR 1988
- CRML N/A
- Country
- PHAR Netherlands
- CRML United States
- Employees
- PHAR N/A
- CRML N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- CRML
- Sector
- PHAR Health Care
- CRML
- Exchange
- PHAR Nasdaq
- CRML NYSE
- Market Cap
- PHAR 731.1M
- CRML 298.8M
- IPO Year
- PHAR N/A
- CRML N/A
- Fundamental
- Price
- PHAR $10.00
- CRML $3.00
- Analyst Decision
- PHAR Strong Buy
- CRML
- Analyst Count
- PHAR 3
- CRML 0
- Target Price
- PHAR $30.00
- CRML N/A
- AVG Volume (30 Days)
- PHAR 3.6K
- CRML 8.0M
- Earning Date
- PHAR 07-31-2025
- CRML 02-01-2025
- Dividend Yield
- PHAR N/A
- CRML N/A
- EPS Growth
- PHAR N/A
- CRML N/A
- EPS
- PHAR N/A
- CRML N/A
- Revenue
- PHAR $320,708,000.00
- CRML $476,979.00
- Revenue This Year
- PHAR $13.31
- CRML N/A
- Revenue Next Year
- PHAR $7.68
- CRML N/A
- P/E Ratio
- PHAR N/A
- CRML N/A
- Revenue Growth
- PHAR 24.13
- CRML 326.80
- 52 Week Low
- PHAR $6.65
- CRML $1.23
- 52 Week High
- PHAR $12.61
- CRML $11.25
- Technical
- Relative Strength Index (RSI)
- PHAR 43.61
- CRML 55.25
- Support Level
- PHAR $9.99
- CRML $2.80
- Resistance Level
- PHAR $10.59
- CRML $3.34
- Average True Range (ATR)
- PHAR 0.35
- CRML 0.46
- MACD
- PHAR -0.14
- CRML -0.05
- Stochastic Oscillator
- PHAR 7.45
- CRML 42.92
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About CRML CRITICAL METALS CORPORATION
Critical Metals Corp is engaged in lithium exploration in Austria. It is focused on the development of its wholly-owned Wolfsberg Lithium Project (the Wolfsberg Project) located in Carinthia, Austria.